Skip to main content
Journal cover image

Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.

Publication ,  Journal Article
Herring, WJ; Roth, T; Krystal, AD; Michelson, D
Published in: J Sleep Res
April 2019

In this review, we outline the role of orexin receptor antagonists in disorders of sleep/wake and other potential neuropsychiatric conditions, with a focus on suvorexant, which is currently the only approved agent in this class. The efficacy of suvorexant was established in Phase 2-3 trials with treatment durations ranging from 1 to 12 months in patients with insomnia. Suvorexant is effective at improving sleep assessed by patient self-report and by polysomnography, with generally little effect on underlying sleep architecture. The main side-effect is next day somnolence. With the growing realization of the important connections between sleep and other disorders, studies are ongoing to explore this novel mechanism in other disorders such as Alzheimer's disease and depression.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Sleep Res

DOI

EISSN

1365-2869

Publication Date

April 2019

Volume

28

Issue

2

Start / End Page

e12782

Location

England

Related Subject Headings

  • Triazoles
  • Sleep Initiation and Maintenance Disorders
  • Orexin Receptor Antagonists
  • Neuropsychiatry
  • Neurology & Neurosurgery
  • Male
  • Humans
  • Female
  • Azepines
  • 52 Psychology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Herring, W. J., Roth, T., Krystal, A. D., & Michelson, D. (2019). Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res, 28(2), e12782. https://doi.org/10.1111/jsr.12782
Herring, W Joseph, Thomas Roth, Andrew D. Krystal, and David Michelson. “Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.J Sleep Res 28, no. 2 (April 2019): e12782. https://doi.org/10.1111/jsr.12782.
Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res. 2019 Apr;28(2):e12782.
Herring, W. Joseph, et al. “Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.J Sleep Res, vol. 28, no. 2, Apr. 2019, p. e12782. Pubmed, doi:10.1111/jsr.12782.
Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res. 2019 Apr;28(2):e12782.
Journal cover image

Published In

J Sleep Res

DOI

EISSN

1365-2869

Publication Date

April 2019

Volume

28

Issue

2

Start / End Page

e12782

Location

England

Related Subject Headings

  • Triazoles
  • Sleep Initiation and Maintenance Disorders
  • Orexin Receptor Antagonists
  • Neuropsychiatry
  • Neurology & Neurosurgery
  • Male
  • Humans
  • Female
  • Azepines
  • 52 Psychology